Sustained molecular response with nilotinib in imatinib-intolerant chronic myeloid leukaemia with an e19a2 BCR-ABL1 fusion
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology,General Medicine
Reference10 articles.
1. First and second line imatinib treatment in chronic myelogenous leukaemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts;Andrikovics;Hematol Oncol,2007
2. A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukaemia at accelerated phase and carrying the e19a2 BCR-ABL transcript;Li;Cancer Genet Cytogenet,2007
3. A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukaemia responding to dasatinib;Cea;Leuk Res,2010
4. Chronic myeloid leukaemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib;Martin;Cancer Genet Cytogenet,2010
5. E255K and G250E mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib;Li;Clin Lab,2015
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Magnetic polymeric core-shell as a carrier for gradual release in-vitro test drug delivery;Heliyon;2021-05
2. Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report;BMC Cancer;2018-12
3. Imatinib/nilotinib;Reactions Weekly;2017-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3